<DOC>
	<DOCNO>NCT01860846</DOCNO>
	<brief_summary>This post marketing observational study ( PMOS ) design collect long-term data work productivity change quality life measurement anti-Tumor Necrosis Factor therapies patient moderate severe Crohn 's disease intolerant or/and unresponsive conventional therapy .</brief_summary>
	<brief_title>Improvement Work Productivity Quality Life With Anti-Tumor Necrosis Factor ( TNF ) Therapies Used Crohn 's Disease Routine Clinical Practice Turkey</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male female patient 1865 year age moderately/severely ( Crohn 's Disease Activity Index 220450 ) active Crohn 's disease with/without fistula formation Patients able provide authorization use disclose information relate study Proven diagnosis Crohn 's Disease accordance international diagnostic criterion European Crohn 's Colitis Organisation ( ECCO ) guideline Patients physician initiate Crohn 's disease treatment antiTumor Necrosis Factors accordance Turkish Ministry Health regulation reimbursement . Subject history kind biological therapy and/or antiTumor Necrosis Factor treatments Crohn 's disease indication Subject septic complication ( active infection and/or active Tuberculosis , undrained abscess ) Patients bowel obstruction fibrotic stricture Subject receive investigational drug within 30 day prior Visit 1 baseline For reason , subject consider investigator unsuitable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Crohn 's disease</keyword>
</DOC>